BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jul 13, 2018
Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
BC Extra | Jul 5, 2018
Clinical News

Zynerba refocusing on CBD gel following failed patch readout

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will focus on developing ZYN002 after single and multiple doses of several formulations of ZYN001 failed to achieve target blood levels of 5-15 ng/mL of tetrahydrocannabinol (THC) in a...
BC Week In Review | Jan 5, 2018
Company News

Zynerba discontinuing ZYN002 and ZYN001 for pain indications

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) said it will discontinue development of ZYN002 to treat osteoarthritis (OA) pain and ZYN001 to treat fibromyalgia and general peripheral neuropathic pain to focus on rare and near-rare neurological and psychiatric...
BC Week In Review | Dec 15, 2017
Clinical News

Zynerba reports additional data for epilepsy candidate ZYN002

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported data from 171 patients with confirmed refractory epilepsy with focal seizures with or without secondary generalization who completed the Phase II STAR 1 trial and were enrolled in the STAR...
BC Week In Review | Sep 29, 2017
Clinical News

Zynerba's ZYN002 meets in Phase II for fragile X

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported top-line data from the open-label Phase II FAB-C trial in 20 children ages 6-17 with fragile X syndrome showing that ZYN002 met the primary endpoint of reducing Anxiety, Depression and...
BC Extra | Sep 28, 2017
Clinical News

Zynerba gains on fragile X syndrome data

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) jumped $3.25 (53%) to $9.44 on Thursday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 met the primary endpoint in the open-label Phase II FAB-C trial to treat children with...
BC Week In Review | Aug 18, 2017
Clinical News

Zynerba's ZYN002 misses in Phase II for OA

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) reported top-line data from the Phase II STOP trial in 320 patients with osteoarthritis (OA) of the knee showing that once-daily 250 and 500 mg doses of ZYN002 each missed the...
BC Extra | Aug 14, 2017
Clinical News

Zynerba misses in Phase II for OA

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) lost $0.61 to $6.42 on Monday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 missed the primary endpoint in the Phase II STOP trial to treat knee pain due to...
BC Week In Review | Aug 11, 2017
Clinical News

Zynerba's ZYN002 misses in Phase II for epilepsy

Zynerba Pharmaceuticals Inc.(NASDAQ:ZYNE) reported top-line data from the Phase II STAR 1 trial in 188 patients with refractory epilepsy showing that 97.5 and 195 mg doses of ZYN002 every 12 hours each missed the primary...
Items per page:
1 - 10 of 22